Novartis has completed the divestiture of its influenza vaccine unit to CSL Limited.. In October 2014, Novartis agreed to divest its influenza vaccines business to CSL Limited for $275 million, a transaction that was part of Novartis’ strategy to divest its vaccines business. Earlier this year Novartis divested its vaccines business (excluding its vaccines influenza business) to GlaxoSmithKline for up to $7.1 billion plus royalties. The $7.1 billion consists of $5.25 billion paid upon completion of the deal, which was completed in March 2015, and up to $1.8 billion in future milestone payments.

Source: Novartis